Cabaletta Bio to Present Updated CABA-201 Data at ACR Convergence 2024

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company specializing in curative targeted cell therapies for autoimmune diseases, is set to deliver two significant presentations at the American College of Rheumatology (ACR) Convergence 2024. The conference will be held at the Walter E. Washington Convention Center in Washington, D.C., from November 14-19, 2024. These presentations will showcase new and updated clinical data on CABA-201, an investigational therapy featuring fully human CD19-CAR T cells with a 4-1BB co-stimulatory domain. CABA-201 is currently under evaluation in various clinical trials that form part of the RESET™ clinical development program.

The first presentation is an oral session titled "Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials." This presentation, identified by Abstract ID 1857177, will take place on Sunday, November 17, 2024, from 3:30 p.m. to 3:45 p.m. ET. It will be presented by Dr. David J. Chang, M.D., M.P.H, FACR, who serves as the Chief Medical Officer at Cabaletta Bio.

The second presentation is a poster session titled "Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials." This poster, identified by Abstract ID 1866605, will be displayed on Saturday, November 16, 2024, from 10:30 a.m. to 12:30 p.m. ET. Dr. Daniel Nunez, Ph.D., who is the Director of Computational Biology at Cabaletta Bio, will present this research.

Attendees and interested parties can access more detailed information, including the accepted abstracts, on the ACR Convergence 2024 website. Following the event, presentation materials will also be made available on the Posters & Publications section of Cabaletta Bio’s website.

CABA-201 is engineered to deplete CD19-positive cells deeply yet temporarily following a single infusion. This targeted cell therapy aims to enable an "immune system reset," potentially leading to durable remission without the need for ongoing treatment in patients with autoimmune diseases. Cabaletta Bio is evaluating CABA-201 across multiple autoimmune conditions under five disease-specific Investigational New Drug applications (INDs) sponsored by the company. These conditions include myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG), and a pemphigus vulgaris (PV) sub-study evaluating CABA-201 without preconditioning.

Cabaletta Bio is dedicated to the discovery and development of engineered T cell therapies aimed at providing deep, durable, and potentially curative treatments for autoimmune diseases. The company's CABA™ platform consists of two main strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, featuring CABA-201 as the lead product candidate, and the CAART (chimeric autoantibody receptor T cells) strategy, which includes multiple clinical-stage candidates such as DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The goal of the CABA™ platform is to develop therapies offering profound and lasting responses for patients with a wide range of autoimmune diseases.

Cabaletta Bio’s headquarters and laboratories are located in Philadelphia, PA.